Summary
Biogen Idec's 2010 10-K report highlights a company focused on neurological disorders with a portfolio driven by AVONEX, TYSABRI, and RITUXAN. Total revenues grew by 7.7% to $4.7 billion, primarily fueled by strong performance in AVONEX and TYSABRI, which saw revenue increases of 8.4% and 16.0% respectively. Despite an overall increase in revenue, income from operations saw a slight decrease of 3.6% due to increased restructuring charges, a significant acquired in-process R&D charge, and higher collaboration profit sharing expenses. The company is undergoing a significant strategic shift, announced in late 2010, to focus primarily on neurology and reallocate R&D resources. This includes terminating or out-licensing oncology and cardiovascular programs and reducing workforce by 13%. Several business development activities occurred in 2010, including the acquisition of Panima Pharmaceuticals AG and new collaboration terms for ocrelizumab and GA101 with Genentech, alongside a license agreement for dexpramipexole. Investors should note the ongoing safety monitoring and regulatory discussions for TYSABRI related to PML risks. Looking ahead, Biogen Idec expects continued competition in the Multiple Sclerosis market and is actively managing its product pipeline and operational structure to drive future growth. The company's financial position remains robust with significant cash reserves, and it actively repurchased shares in 2010.
Financial Highlights
56 data points| Revenue | $4.72B |
| Cost of Revenue | $400.26M |
| Gross Profit | $4.32B |
| R&D Expenses | $1.25B |
| SG&A Expenses | $1.03B |
| Operating Expenses | $3.47B |
| Operating Income | $1.25B |
| Interest Expense | $36.10M |
| Net Income | $1.01B |
| EPS (Basic) | $3.98 |
| EPS (Diluted) | $3.94 |
| Shares Outstanding (Basic) | 252.31M |
| Shares Outstanding (Diluted) | 254.87M |
Key Highlights
- 1Total revenues increased 7.7% to $4.7 billion in 2010, driven by strong sales of AVONEX (up 8.4%) and TYSABRI (up 16.0%).
- 2Net income attributable to Biogen Idec Inc. increased 3.6% to $1.0 billion.
- 3Diluted EPS increased 17.6% to $3.94.
- 4Company announced a strategic restructuring initiative to focus on neurology, reallocate R&D, and reduce workforce by approximately 13%, with expected annual savings of $300 million.
- 5Significant investment in R&D continues, with $1.25 billion spent in 2010, including a $205 million charge related to the Knopp acquisition.
- 6TYSABRI sales growth continues despite significant safety warnings related to PML, with ongoing efforts to stratify patient risk.
- 7RITUXAN revenues saw a slight decrease of 1.6%, largely due to royalty expirations in rest-of-world markets, although U.S. co-promotion profits increased.
- 8Acquisition of Panima Pharmaceuticals AG completed in December 2010 for up to $395 million in contingent consideration.